PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 23, 2026Drug and Alcohol Dependence0 citationsOpen Access

Plasma cannabinoid pharmacokinetics following the inhalation of vaporised cannabis with and without cannabidiol

View Full Paper
DHDaniel HallECEdward; id_orcid 0000-0003-2851-5252 ChesneyCMClaire Mokrysz

Key Points

  • This research aims to investigate how cannabidiol (CBD) affects plasma levels of THC and its metabolites and how these effects differ across age groups.
  • Conducted a randomised, double-blind, placebo-controlled, cross-over study with 48 participants.
  • Examined three vaporized cannabis preparations: THC-alone, THC+CBD, and placebo.
  • Collected blood samples at various time points after inhalation to measure cannabinoid concentrations.
  • The ‘THC+CBD’ condition resulted in significantly higher plasma levels of THC, OH-THC, and COOH-THC compared to ‘THC-alone’.
  • There was no strong evidence of age-related differences in pharmacokinetics.
  • CBD presence increased circulating THC and metabolite levels after vaporised cannabis inhalation.

Abstract

The presence of cannabidiol (CBD) in cannabis may alter cannabinoid pharmacokinetics, however previous research has produced mixed results. Furthermore, no prior research has explored how cannabinoid pharmacokinetics are moderated by age. Using vaporised and inhaled cannabis, we aimed to (1) examine the effect of CBD on the plasma concentration of delta-9-tetrahydrocannabinol (THC) and its metabolites, and (2) compare cannabinoid plasma pharmacokinetics in adolescents and adults. We conducted a randomised, double-blind, placebo-controlled, cross-over study. We compared the effects of three vaporized, weight-adjusted cannabis preparations: ‘THC-alone’ (8 mg THC/75 kg), ‘THC+CBD’ (8 mg THC and 24 mg CBD/75 kg) and placebo, in 48 participants, aged 16-17-years and 26-29-years. Blood samples were taken prior to inhalation, then 20, 30, and 160 minutes after inhalation began. Thirty-five participants had complete pharmacokinetic datasets, which were analysed. Plasma was analysed for concentrations of THC, 11-hydroxy-THC (OH-THC) and 11-Nor-9-carboxy-THC (COOH-THC), CBD, 7-hydroxy-cannabidiol (OH-CBD) and 7-carboxy-cannabidiol (COOH-CBD). The ‘THC+CBD’ condition produced significantly greater THC, OH-THC, and COOH-THC plasma levels than the ‘THC-alone’ condition, in terms of natural-log-transformed area-under-the-curve (AUC) and peak concentration (C max ) values, with the exception of C max for OH-THC. Geometric mean ratios showed the ‘THC+CBD’ condition led to higher THC plasma levels. There was no strong evidence of age-related differences. The presence of CBD in vaporised cannabis increased circulating levels of THC and THC-metabolites. However, further research is needed to understand discrepancies between results from different studies. • CBD increased THC plasma levels, after inhalation of vaporised cannabis. • CBD increased THC metabolite levels, after inhalation of vaporised cannabis. • No evidence that cannabinoid pharmacokinetics differed between teenagers and adults.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hall et al. (2026) studied this question.

synapsesocial.com/papers/69e9b71b85696592c86eb2d1https://doi.org/10.1016/j.drugalcdep.2026.113160
Ask AI
Helpful
Bookmark
Share
View Full Paper